No Data
No Data
Quince Therapeutics Launches Scientific Advisory Board
World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company's lead Phase 3 asset, new indications, and pipeline expansion Quince Therapeutics, Inc.
Quince Therapeutics Appoints Rajiv Patni to Board of Directors
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to Its Board of Directors
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a pat
Quince Therapeutics to Participate at Investor Events in January 2024
Quince Therapeutics On Dec. 22 Board Approved Certain Mutual Termination Of License Agreement By And Between Co, Purdue Research Foundation
Quince Therapeutics On Dec. 22 Board Approved Certain Mutual Termination Of License Agreement By And Between Co, Purdue Research Foundation
No Data